Medvi is a telehealth service that pairs an online visit with compounded GLP-1 medication, most often tirzepatide, shipped from a partner pharmacy. The sign-up is fast and the advertised monthly price is low, but the medication is not an FDA-approved product, the introductory rate is not the price most people keep paying, and the value depends entirely on whether you have a coverage alternative. That is the short version. The rest is worth reading if you are weighing it against the field.
What are you actually signing up for?
The flow is familiar to anyone who has used a direct-to-consumer health site. You fill in a health questionnaire, enter payment details, and a licensed clinician reviews your case before anything ships. What arrives, in the common case, is compounded tirzepatide rather than a boxed pharmacy brand. That single fact reframes most Medvi reviews, because it decides both the price and the risk profile.
Compounded medication is prepared by a compounding pharmacy for an individual patient. It is not made under an approved application, and the FDA does not verify its safety, effectiveness, or quality the way it does for an approved drug. The agency’s own explainer on compounding is blunt about that gap. This is not a knock on any one company. It is the category the whole model lives in.
Is the medication the same as the brand?
The active molecule can be the same as the one in Zepbound. The evidence base is not. The brand’s approval rests on trials like SURMOUNT-1, which showed substantial weight reduction with tirzepatide over 72 weeks, and was supported by later work such as the SURMOUNT-CN trial in Chinese adults with obesity. There is also useful comparative work: a 2024 analysis in semaglutide versus tirzepatide for weight loss found tirzepatide produced greater average reductions in a real-world cohort. None of those trials studied a compounded version. Buying compounded tirzepatide means buying the molecule without the specific product that generated that record.
The maintenance question matters too. SURMOUNT-4 showed that stopping tirzepatide led to substantial weight regain, while continuing it preserved most of the loss. That is a long-term commitment regardless of who prescribes it, which makes the sustainable monthly cost more important than the first bill.
What does it cost, really?
The advertised entry price is generally honest for month one. The catch is that tirzepatide is titrated upward over time, and compounded pricing frequently rises with the dose. The figure to write down is what you would pay at a maintenance dose several months in, not the promotional rate. Ask directly, in writing, before you enter a card number.
| Route | What sets the price | Main limitation |
|---|---|---|
| Insurance-covered brand | Formulary tier, deductible, prior authorization | Many plans exclude weight management drugs |
| Manufacturer self-pay brand | Fixed cash price set by the maker | Refill-timing and dose conditions apply |
| Compounded telehealth (Medvi and peers) | Service fee plus pharmacy pricing, often dose-based | Not an FDA-approved product |
How does it sit against the rest of the field?
Medvi is one of many services doing roughly the same thing. Hims and Hers, Ro, Henry Meds, and others sell compounded or brand GLP-1 access through telehealth, while LillyDirect and NovoCare route people to the manufacturers’ own self-pay brand programs. Prices and prescribing quality vary more than the marketing suggests. For readers comparing the compounded tirzepatide services specifically, a side-by-side breakdown such as an honest look at Medvi lays out the dose-based pricing structure that the sign-up page tends to gloss over. The point of comparing is not brand loyalty. It is finding a supervised program whose maintenance price and prescriber access hold up.
One legitimate use of these services is access. For patients whose plans exclude anti-obesity medication, a physician-supervised compounded route can be the only affordable path to the molecule. That is a real benefit, and it deserves to be stated as plainly as the risks.
What do the safety reports say?
This is where the honest reviews earn their keep. The recurring problem with compounded GLP-1 medication is not the molecule, it is the delivery. A case series from a poison control center documented administration errors with compounded semaglutide, including patients drawing up the wrong volume from multi-dose vials and dosing in the wrong units. A broader pharmacovigilance study using the FDA adverse event reporting system examined safety signals tied to compounded GLP-1 products. And a 2025 clinical review on what providers need to know about compounded semaglutide stresses the same theme: variable concentrations and unfamiliar syringes create room for error that boxed pens are designed to prevent.
The takeaway is not that compounded tirzepatide is unusable. It is that the safety of the experience leans heavily on clear instructions, a reachable prescriber, and a product that arrives in a form you can dose confidently. A service that ships a vial with thin guidance is riskier than its price suggests, whatever the label on the box.
What kind of medicine is behind it?
Tirzepatide belongs to the incretin class now central to type 2 diabetes and obesity care. A review of drugs for type 2 diabetes traces how these agents earned their place, and that clinical foundation is genuine. What a compounded version does not carry is the specific manufacturing and testing chain that stands behind the approved product. That distinction is easy to lose when a slick sign-up flow makes everything feel equivalent.
Is it worth it?
For someone with no coverage and a clear-eyed understanding of the trade, Medvi and its peers can be a reasonable way to reach supervised treatment. For someone whose insurance already covers brand tirzepatide, or who wants the assurance of an approved product, this is the wrong door, and no promotional price changes that. The best of the Medvi reviews say the same thing in different words: judge it on the maintenance price and the quality of prescriber contact, not the headline number.
Key takeaways
- Medvi sells a telehealth visit plus compounded tirzepatide, which is not an FDA-approved product.
- The intro price is real for month one; the dose-adjusted maintenance price is the number that matters.
- Documented risks center on dosing and administration errors, not the molecule itself.
- If insurance covers brand tirzepatide, a compounded route trades away the assurance you are paying for.
See also: 5 Common Mistakes Businesses Make with Wholesale N2O (And How to Fix Them)
Frequently asked questions
What does Medvi actually sell?
A telehealth service that connects patients with a prescriber and, in many cases, arranges compounded GLP-1 medication through a partner pharmacy. It is a service and a prescription, not a branded FDA-approved drug sold off a shelf.
Is the medication the same as Zepbound?
No. Compounded tirzepatide may use the same active molecule, but it is prepared by a compounding pharmacy and is not an FDA-approved product. It has not gone through the approval process behind the published brand trials.
Are the low monthly prices real?
The introductory figure is usually real for the first month. The sustainable price after dose increases and past any promotion is the number worth checking, since that is what most people end up paying.
Do Medvi reviews flag any safety issues?
The most consistent concerns across compounded GLP-1 services are dosing confusion and administration errors, which are documented in poison control and pharmacovigilance reports rather than being specific to one company.
Who is this a poor fit for?
Anyone whose insurance already covers brand tirzepatide, and anyone who wants the regulatory assurance of an approved product. For them a compounded route trades away the thing they most want.
